Cargando…

Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis

BACKGROUND: While considered the mainstay of treatment for specific bone metastases, ZA is used predominantly to treat osteolytic lesions. The purpose of this network meta-analysis is to compare ZA to other treatment options in its ability to improve specific clinical outcomes in patients with bone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorange, Justin-Pierre, Ramirez Garcia Luna, Jose, Grou-Boileau, Frédéric, Rosenzweig, Derek, Weber, Michael H., Akoury, Elie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969300/ https://www.ncbi.nlm.nih.gov/pubmed/36860585 http://dx.doi.org/10.1016/j.jbo.2023.100470

Ejemplares similares

Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
por: Akoury, Elie, et al.
Publicado: (2019)

Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis
por: Akoury, Elie, et al.
Publicado: (2019)

Nanoporous 3D-Printed Scaffolds for Local Doxorubicin Delivery in Bone Metastases Secondary to Prostate Cancer
por: Ahangar, Pouyan, et al.
Publicado: (2018)

Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration
por: Nooh, Anas, et al.
Publicado: (2017)

The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis
por: Hadji, P., et al.
Publicado: (2012)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Zoledronic acid in the management of metastatic bone disease
por: Polascik, Thomas J, et al.
Publicado: (2008)

Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis
por: Richhariya, Akshara, et al.
Publicado: (2012)

Preventive Effects of Zoledronic Acid on Bone Metastasis in Mice Injected with Human Breast Cancer Cells
por: Jeong, Joon, et al.
Publicado: (2011)

Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis
por: Haider, Marie-Therese, et al.
Publicado: (2014)

Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review
por: Wang, Lianwei, et al.
Publicado: (2020)

Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo
por: Landgraf, Marietta, et al.
Publicado: (2019)

Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis
por: Cao, Ling, et al.
Publicado: (2017)

Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone
por: Giveon, Sharon, et al.
Publicado: (2023)

Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China
por: Wang, Qianyu, et al.
Publicado: (2020)

Correction: Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of Zoledronic acid in vivo
por: Landgraf, Marietta, et al.
Publicado: (2020)

Correction: Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis
por: Cao, Ling, et al.
Publicado: (2018)

Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis
por: Yang, Liqing, et al.
Publicado: (2015)

Endometrial Cancer Diagnosed by the Presence of Bone Metastasis and Treated with Zoledronic Acid: A Case Report and Review of the Literature
por: Shigemitsu, Aiko, et al.
Publicado: (2010)

Zoledronic Acid Versus Denosumab for Prevention of Spinal Cord Compression in Advanced Cancers With Spine Metastasis: A Meta-Analysis of Randomized Controlled Trials
por: Al Farii, Humaid, et al.
Publicado: (2019)

Zoledronic Acid Preserves Bone Structure and Increases Survival but Does Not Limit Tumour Incidence in a Prostate Cancer Bone Metastasis Model
por: Hung, Tzong-Tyng, et al.
Publicado: (2011)

Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer
por: Duivenvoorden, W C M, et al.
Publicado: (2007)

Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis
por: Juárez, Patricia, et al.
Publicado: (2017)

Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study
por: Nasser, Sahar M, et al.
Publicado: (2019)

Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid
por: Aft, Rebecca
Publicado: (2012)

Zoledronic acid for prevention of bone loss in patients receiving bariatric surgery
por: Liu, Yi, et al.
Publicado: (2021)

Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
por: Park, Jung-Wee
Publicado: (2021)

Zoledronic Acid Implant Coating Results in Local Medullary Bone Growth
por: Quarterman, Juliana C., et al.
Publicado: (2022)

The effect of zoledronate during bone healing
por: Matos, Marcos Almeida, et al.
Publicado: (2010)

Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption
por: Huang, Yanjuan, et al.
Publicado: (2020)

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials
por: Jiang, Lianghai, et al.
Publicado: (2021)

Effect of intravenous administration of zoledronic acid on jaw bone density in cases having skeletal metastasis: A prospective clinical study
por: Jain, Veena, et al.
Publicado: (2019)

Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023)

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
por: Lambrinoudaki, Irene, et al.
Publicado: (2008)

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass
por: Hamdy, Ronald C
Publicado: (2010)

Guided bone regeneration with local zoledronic acid and titanium barrier: An experimental study
por: Dundar, Serkan, et al.
Publicado: (2016)

The anti-tumour effects of zoledronic acid
por: Zekri, Jamal, et al.
Publicado: (2014)

Zoledronic Acid–Induced Interface Dermatitis
por: Succaria, Farah, et al.
Publicado: (2015)

Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions
por: George, Christopher N., et al.
Publicado: (2020)

Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cm139okb1toianjkn0iqh048ul